Address
18702 North Creek Parkway
Bothell, WA 98011
United States of America (the)
Phone
610 321 3700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
177
First IPO Date
October 02, 2020
| Name | Title | Pay | Year Born |
| Clay Siegall | Chairman, President & Chief Executive Officer | 1.41M | 1961 |
| Kinney Horn | Chief Business Officer | 598,862 | 1975 |
| Sandra G. Stoneman | Chief Legal Officer, General Counsel & Corporate Secretary | 715,350 | 1973 |
| Robert J. Lechleider | Chief Medical Officer | 850,093 | 1961 |
| Jack Higgins | Chief Scientific Officer | 956,342 | 1980 |
| Max Rosett | Chief Financial Officer | 1.16M | 1990 |
| Roee Shahar | Executive Vice President of Commercial | 0 | N/A |
| Philip Tsai | Chief Technical Officer | 0 | 1968 |
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.